LDS/Medical Tests/TACSTD2 Gene Mutation Analysis

TACSTD2 Gene Mutation Analysis

The TACSTD2 gene located on the short (p) arm of chromosome 1 at position 32.1 encodes tumor-associated calcium signal transducer 2, also known as Trop-2 and epithelial glycoprotein-1 antigen (EGP-1). The TACSTD2 protein is a monomeric cell surface glycoprotein, localized at the cell-to-cell borders of all squamous epithelium including skin, conjunctiva, cornea, oropharyngeal and esophageal linings, uterine cervix and vagina. Mutations of this gene results in gelatinous drop-like corneal dystrophy also termed lattice corneal dystrophy II which is a form of ocular amyloidosis.

Gelatinous, drop-like corneal dystrophy (GDLD) is a rare autosomal recessive disorder that is most common in individuals of Japanese ancestry with estimated prevalence of 1 in 300,000. It is a form of lattice corneal dystrophy, a class of inherited stromal amyloidosis characterized by pathognomonic branching lattice-like deposits in the cornea. Clinically, deposits usually appear in the first decade of life resulting in blurred vision, photophobia, foreign-body sensation, and yellow-grayish, mulberry-like protruding corneal depositions of amyloid. The disorder is progressive and eventually results in blindness without corneal transplantation. Similar clinical features may be seen with mutations that involve the genes for gelsolin (FAF), and transforming growth factor beta – induced protein (TGFB1).

  • Diagnostic confirmation of TACSTD2 gene- associated gelatinous drop-like corneal dystrophy
  • For the prenatal genetic test in an individual at risk of gelatinous drop-like corneal dystrophy
  • For preimplantation genetic diagnosis of corneal dystrophy

Positive: Mutation or pathogenic variant in TACSTD2 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative: No mutation or pathogenic variant in TACSTD2 gene.

Negative for mutation or pathogenic variant in TACSTD2 gene

Sequence analysis by next generation sequencing or bi-directional sequencing. TACSTD2 gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood, amniotic fluid (prenatal test).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Corneal Dystrophy Gene Mutation Panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login